OPTIMAL: A Multinational Phase III Study of Oral Paclitaxel (DHP107) versus Intravenous Weekly Paclitaxel in HER2-Negative Recurrent or Metastatic Breast Cancer
医学
转移性乳腺癌
内科学
肿瘤科
紫杉醇
临床研究阶段
化疗
乳腺癌
化疗方案
转移
癌症
乳腺
作者
B. Xu,H. Jeong,T. Sun,J. Sohn,Q. Zhang,S. Kostic,X. Wang,Z. Tong,S. Wang,J. Wang,W. Li,K.S. Lee,Y.W. Moon,M.J. Kang,X Hu,T.Y. Kim,D. Milenković,J.H. Seo,J.H. Kim,J. W. Lee
DHP107 demonstrated non-inferior efficacy compared to IV paclitaxel, with a manageable safety profile, supporting its use as an effective and convenient alternative in HER2-negative breast cancer.
PDF的下载单位、IP信息已删除
(2025-6-4)
cdercder
FIN
OK
GingerF
XX
Criminology34
Kao
秋风
斯文的白玉
归零者
无极微光
Nole
null
wonder
罗Eason
爱听歌凤灵
adcffgg
heekkll
小荷才露尖尖角
牧青
皖公网安备34019202002308
